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key parameters for wound healing.
Overlaying the immobilized EGF with
increasing numbers of bilayers of PAH
and PAA diminished the proliferative
response, but did not alter the migratory
response, suggesting that the PEM plat-
form can be tuned to target-specific cell
responses. Further experiments are
needed to investigate this difference.
The EGF conjugated to PEMs can target
cellular-reparative responses to acceler-
ate wound healing, while avoiding
many of the concerns associated with
systemic delivery and systemic diffusion
of free growth factors. PEMs represent
facile materials platform for integration
into wound therapeutic strategies, and
can incorporate other bioactives, (e.g.,
antimicrobial silver nanoparticles)
(Agarwal et al., 2010), providing the
potential for translation into a clinical
approach to improve healing in patients
with chronic wounds.
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TO THE EDITOR
Recurrent respiratory papillomatosis
(RRP), a disease characterized by recur-
rent tumors of the upper airway, is
caused by human papillomavirus
(HPV) types 6 and 11 (Doorbar et al.,
2012). It has been suggested that the
HPV early protein E6 regulates the
function of the oncogene b-catenin,
including a recent report, which shows
that HPV16 E6 can induce nuclear
localization of b-catenin in a cuta-
neous mouse model (Bonilla-Delgado
et al., 2012). b-catenin’s function in the
cell is highly dependent on its
localization (Brembeck et al., 2006).Accepted article preview online 29 January 2014; published online 27 February 2014
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At the plasma membrane, b-catenin
mediates the interaction of the adherens
junctions, which bind neighboring cells
together, and the actin cytoskeleton,
which is responsible for organizing
internal structures of the cell (Meng and
Takeichi, 2009). When b-catenin trans-
locates to the nucleus, it functions as an
oncogene because it activates transcrip-
tion of a number of genes that are impo-
rtant in proliferation and migration. It is
not known whether the ‘‘low-risk’’ HPVs
6 and 11 induce b-catenin’s nuclear loca-
lization. We have addressed this question
by comparing biopsies of respiratory
papillomas with normal tissues from the
same patients.
b-Catenin localization was deter-
mined by immunofluorescence, using
E-cadherin as a marker of the plasma
membrane and 40,6-diamidino-2-phenyl-
indole dihydrochloride (DAPI) to mark
the nuclei (Figure 1a). There was very
strong colocalization of b-catenin with
E-cadherin at the plasma membrane but
no evidence of nuclear localization,
suggesting that b-catenin was not
induced to translocate to the nucleus
by HPV 6/11. The localization of b-
catenin at the plasma membrane was
observed in all papillomas analyzed,
regardless of age of onset or severity of
the papillomatosis. To confirm that b-
catenin target genes are not upregulated
in papillomas, we reassessed data from
our previously published microarray
studies that compared mRNA isolated
from matched pairs of papillomas
and normal laryngeal tissues from 12
RRP patients (DeVoti et al., 2008).
The microarrays included probes for
15 of the confirmed human b-catenin
transcriptional targets: myc, cyclin D1,
c-jun, uPAR, CD44, ephrin B1,
claudin1, vascular endothelial growth
factor (VEGF), Met, Endothelin-1,
Jagged 1, FGF9, FGF20, Sox9, and
Sox17 (Nusse, 2009). Of these, only
VEGF was modestly upregulated (data
not shown). However, VEGF can be
induced by activation of the epidermal
growth factor receptor, via transcription
factors SP1 and AP2 (Pore et al., 2006).
As the epidermal growth factor receptor
is overexpressed and highly active in
papillomas (Johnston et al., 1999), it is
likely that VEGF was being induced by
this mechanism and not by b-catenin
activity.
We noted increased intensity of
b-catenin staining in papilloma tissues
compared with clinically normal tissues
from the same patients, which was
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Figure 1. b-Catenin localizes to the plasma membrane in respiratory papillomas. (a) Papilloma and clinically normal tissue from the same patient were stained for
b-catenin (red) and E-cadherin (green). 40,6-Diamidino-2-phenylindole dihydrochloride (DAPI) (blue) was used to stain the nucleus. Scale bars¼20mm. (b)
Representative western blots of biopsies of clinically normal tissue (CN) and papilloma tissue (P) from recurrent respiratory papillomatosis (RRP) patients. (c)
Relative b-catenin mRNA levels normalized to GAPDH. (d, e) Western blots of phospho-glycogen synthase kinase 3b (GSK-3b) and protein kinase G (PKG),
respectively. N indicates normal samples from a non-RRP patient. Donors of the tissues were numbered sequentially. CN6a and CN6b were clinically normal
tissues from two sites in the airway of patient 6. Actin was used as a loading control.
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confirmed by western blot analysis
(Figure 1b). We therefore investigated
the mechanism by which HPV 6/11
induced b-catenin overexpression.
There was no elevation of b-catenin
mRNA levels in papilloma tissues
(Figure 1c), suggesting increased protein
stability. Two proteins phosphorylate
b-catenin, targeting it for degradation:
glycogen synthase kinase 3b (GSK-3b)
and protein kinase G (PKG) (Heuberger
and Birchmeier, 2010). Phosphoryla-
tion of GSK-3b was highly eleva-
ted in the papillomas (Figure 1d), and
phophorylated GSK-3b is inactive.
Moreover, PKG levels were generally
lower in papillomas (Figure 1e). Thus,
HPV 6/11 infection effectively sup-
presses both mediators of b-catenin
degradation, inactivating one kinase
and reducing the levels of the other.
The second known role for b-catenin
is the organization of the actin cytoske-
leton. In biopsies of clinically normal
tissue from papilloma patients, actin
showed clear cortical staining around
each cell. In contrast, its distribution in
the cells of papilloma biopsies was
diffuse and cytoplasmic (Figure 2a).
Total actin levels do not differ signifi-
cantly between papilloma cells and
normal cells (data not shown). a-cate-
nin, which mediates b-catenin’s recruit-
ment of actin to the plasma mem-
brane (Hartsock and Nelson, 2008),
was also more cytoplasmically diffuse
in papillomas (Figure 2b). We therefore
suggest that the increased b-catenin in
respiratory papillomas results in, or is
associated with, its decoupling from the
actin cytoskeleton. Additional work
needs to be done to determine the
mechanism of this decoupling.
Interestingly, there is a growing body of
literature that suggests that the actin cyto-
skeleton is an active regulator of differ-
entiation of cells in a stratified epithelium.
siRNA depletion of ROCK2, a serine/
threonine kinase that regulates the cyto-
skeleton and cell adhesion, suppresses
terminal differentiation of keratinocytes
(Lock and Hotchin, 2009) Conversely,
activation of ROCK2 promotes differen-
tiation (McMullan et al., 2003). More
direct evidence comes from a study
showing that the disruption of actin fila-
ments using latrunculin A results in
aberrant expression of differentiation
markers (Pedersen et al., 2012). We
have previously reported that differentia-
tion is altered in respiratory papillomas
(Steinberg et al., 1990), and others have
reported that HPV pathogenicity is
dependent on altering the differentiation
pattern (Longworth and Laimins, 2004). It
is clear that the low-risk HPVs are not
causing nuclear translocation of b-catenin
in respiratory papillomas. Rather, we
postulate that they regulate the actin
cytoskeleton through manipulation of b-
catenin at the cell membrane as a
mechanism for altering differentiation.
All Helsinki protocols were followed
in the human subjects research. Tissues
were obtained from patients undergoing
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Figure 2. a-Catenin and actin are mislocalized in recurrent respiratory papillomatosis (RRP). Immunofluorescent images of papilloma and clinically normal
tissue from the same patient stained for b-actin (green) and 40,6-diamidino-2-phenylindole dihydrochloride (DAPI) to stain the nucleus (blue) (a) or a-catenin (red) and
E-cadherin (green) (b). Scale bars¼ 5mm.
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surgery in the Department of Otolaryn-
gology at Long Island Jewish (LIJ) Med-
ical Center after written, informed
consent. Use of these tissues was
approved by the Institutional Review
Board of the Feinstein Institute for Med-
ical Research.
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TO THE EDITOR
Metastatic melanoma is notorious for
its rapid progression, resistance to con-
ventional chemotherapy, and poor prog-
nosis, as only 14% of patients with
metastatic melanoma survive for 5 years
(Miller and Mihm, 2006). There has been
limited success in the chemotherapy
of melanoma, with only a hand-
ful of Food and Drug Administration-
approved drugs (Finn et al., 2012).
Although BRAFV600E-specific inhibitor,
vemurafinib showed promise in treat-
ment of melanoma, its effectiveness
has been limited to patients harboring
the V600E mutation in BRAF gene;
moreover, recent information suggest
the development of lethal resistance to
vemurafinib (Finn et al., 2012). It was
shown earlier that BRAF inhibits the
activation of AMP-activated protein
kinase (AMPK; Zheng et al., 2009).
AMPK is a key regulator of cell metabo-
lism and its activation has been reported
to have antineoplastic effects (Kim and
He, 2013). However, the role of AMPK
in cancer has been controversial with
studies showing the ‘prosurvival’ effects
of AMPK (Liang and Mills, 2013), and
only a few studies reported on the
relationship between AMPK expression
and cancer progression. To our knowl-
edge, AMPK expression has never been
analyzed in melanoma patients. AMPK
consists of catalytic a-subunit and regu-
latory b- and g-subunits, and in mam-
mals, each subunit occurs as multiple
isoforms (Kim and He, 2013). AMPKa1
is reportedly associated with tumor sup-
pressor functions of AMPK (Lee et al.,
2010; Liang and Mills, 2013; Zheng
et al., 2013) and the present study
was therefore undertaken to analyze
the correlation between AMPKa1
expression and patient survival using
the tissue samples collected from mela-
noma patients.
We performed tissue microarray
analysis of AMPKa1 expression in 128Accepted article preview online 17 January 2014; published online 13 February 2014
Abbreviations: AMPK, AMP-activated protein kinase; IRS, immunoreactive score
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